ORKA (Oruka Therapeutics) Current Accrued Expense: $11.42 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORKA Oruka Therapeutics Inc ORKA
12 GF Score
Price $92.13
! 1 Warning Sign
View Full Analysis

What is Oruka Therapeutics Current Accrued Expense?

Oruka Therapeutics ORKA -0.55% 12 Current Accrued Expense is $11.42 Mil as of Jun. 2026. GuruFocus rates ORKA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Oruka Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was $11.42 Mil.

Oruka Therapeutics's quarterly Current Accrued Expense increased from Dec. 2025 ($5.33 Mil) to Mar. 2026 ($7.58 Mil) and increased from Mar. 2026 ($7.58 Mil) to Jun. 2026 ($11.42 Mil).

Oruka Therapeutics's annual Current Accrued Expense increased from . 20 ($0.00 Mil) to Dec. 2024 ($1.31 Mil) and increased from Dec. 2024 ($1.31 Mil) to Dec. 2025 ($5.33 Mil).

Oruka Therapeutics Current Accrued Expense Related Terms

Oruka Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Oruka Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oruka Therapeutics Current Accrued Expense Chart

Oruka Therapeutics Annual Data
Trend Dec24 Dec25
Current Accrued Expense
1.31 5.33

Oruka Therapeutics Quarterly Data
Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.89 5.80 5.33 7.58 11.42
ORKA
12GF Score
Oruka Therapeutics Inc ORKA
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oruka Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $11.42 Mil mean?
Oruka Therapeutics (ORKA) has a Current Accrued Expense of $11.42 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Oruka Therapeutics and its competitors.
Is Oruka Therapeutics' Current Accrued Expense too high?
Oruka Therapeutics' current Current Accrued Expense is $11.42 Mil. Overall, Oruka Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Oruka Therapeutics' Current Accrued Expense compare to COGT and MIRM?
Oruka Therapeutics' Current Accrued Expense of $11.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Oruka Therapeutics and its competitors. Oruka Therapeutics's current Current Accrued Expense is $11.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oruka Therapeutics stock overvalued right now?
Oruka Therapeutics (ORKA) has a current Current Accrued Expense of $11.42 Mil. The current Current Accrued Expense is $11.42 Mil. Oruka Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Oruka Therapeutics (ORKA), the current Current Accrued Expense is $11.42 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oruka Therapeutics Business Description

Other Exchanges HQ1:Germany
Address 855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
12GF Score

Get the complete analysis for ORKA

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$92.13
Price